Immunization of horses with a high-antigen EHV-1 vaccine decreased clinical signs of infection when challenged with a neuropathogenic strain of EHV-1, although differences were not statistically signifi- cant. A larger number of horses would be needed for conclusive evidence of the ability of vaccination to protect horses from equine herpes myeloencepha- lopathy. However, the present pilot study provides justification for a more extensive and definitive study.
Acknowledgment This study was funded by Zoetis Animal Health.
Footnote a
49007. Pneumabort-K®, Zoetis Animal Health, Kalamazoo, MI